Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 1
1969 2
1970 2
1971 3
1972 2
1980 2
1981 1
1982 3
1983 1
1984 2
1985 1
1986 1
1989 2
1990 4
1991 1
1992 4
1993 4
1994 7
1995 3
1996 3
1997 1
1998 5
1999 2
2000 5
2001 1
2002 7
2003 3
2004 6
2005 8
2006 9
2007 6
2008 8
2009 11
2010 13
2011 17
2012 18
2013 15
2014 26
2015 23
2016 15
2017 16
2018 9
2019 12
2020 20
2021 13
2022 8
2023 7
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

299 results

Results by year

Filters applied: . Clear all
Page 1
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk, et al. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. Lancet. 2023. PMID: 37061269 Free PMC article.
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Iwase T, Saji S, Iijima K, Higaki K, Ohtani S, Sato Y, Hozumi Y, Hasegawa Y, Yanagita Y, Takei H, Tanaka M, Masuoka H, Tanabe M, Egawa C, Komoike Y, Nakamura T, Ohtsu H, Mukai H. Iwase T, et al. Among authors: hozumi y. J Clin Oncol. 2023 Jun 20;41(18):3329-3338. doi: 10.1200/JCO.22.00577. Epub 2023 Apr 20. J Clin Oncol. 2023. PMID: 37079878 Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Decoding Asymptomatic COVID-19 Infection and Transmission.
Wang R, Chen J, Hozumi Y, Yin C, Wei GW. Wang R, et al. Among authors: hozumi y. J Phys Chem Lett. 2020 Dec 3;11(23):10007-10015. doi: 10.1021/acs.jpclett.0c02765. Epub 2020 Nov 12. J Phys Chem Lett. 2020. PMID: 33179934 Free PMC article. Review.
Emerging dominant SARS-CoV-2 variants.
Chen J, Wang R, Hozumi Y, Liu G, Qiu Y, Wei X, Wei GW. Chen J, et al. Among authors: hozumi y. ArXiv [Preprint]. 2022 Oct 18:arXiv:2210.09485v1. ArXiv. 2022. PMID: 36299737 Free PMC article. Updated. Preprint.
Emerging Dominant SARS-CoV-2 Variants.
Chen J, Wang R, Hozumi Y, Liu G, Qiu Y, Wei X, Wei GW. Chen J, et al. Among authors: hozumi y. J Chem Inf Model. 2023 Jan 9;63(1):335-342. doi: 10.1021/acs.jcim.2c01352. Epub 2022 Dec 28. J Chem Inf Model. 2023. PMID: 36577010 Free PMC article.
Emerging Vaccine-Breakthrough SARS-CoV-2 Variants.
Wang R, Chen J, Hozumi Y, Yin C, Wei GW. Wang R, et al. Among authors: hozumi y. ACS Infect Dis. 2022 Mar 11;8(3):546-556. doi: 10.1021/acsinfecdis.1c00557. Epub 2022 Feb 8. ACS Infect Dis. 2022. PMID: 35133792 Free PMC article.
Mutations on COVID-19 diagnostic targets.
Wang R, Hozumi Y, Yin C, Wei GW. Wang R, et al. Among authors: hozumi y. Genomics. 2020 Nov;112(6):5204-5213. doi: 10.1016/j.ygeno.2020.09.028. Epub 2020 Sep 20. Genomics. 2020. PMID: 32966857 Free PMC article.
299 results